ArticleCrohn's & colitis 3602026
Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dual-Targeted Therapy in Refractory Pyoderma Gangrenosum: A Focused Systematic Review of Convergent Pathway Targeting.Dermatology and therapy · 2026Pooled it
- Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are significant unmet needs for the treatment of Crohn's disease (CD). We have previously described a novel dual-targeted therapy (DTT) of the interleukin-12/23 (IL-12/23) inhibitor ustekinumab and selective Janus kinase 1 inhibitor upadacitinib (UPA). Here, we evaluate the safety and effectiveness of the IL-23 inhibitor risankizumab (RISA) combined with UPA in patients with CD. Methods: We retrospectively analyzed data from our prospectively collected real-world database of patients with CD at the [Institution Name] treated with the combination of RISA and UPA from November 05, 2021 to September 18, 2024. Clinical response and remission, extraintestinal manifestation outcomes, and adverse events were evaluated in all patients, including ileostomy patients. Results: Nineteen patients with CD were treated with RISA and UPA (median age 38 years [interquartile range, IQR 33.5-43.5], 13/19 [68%] female, median disease duration at DTT initiation 14.1 years [IQR 10.9-22.8], 14/19 [73.7%] had prior inflammatory bowel disease [IBD] surgeries, 5/19 [26.3%] had ileostomies). At DTT initiation, most patients had been treated previously with more than 4 prior advanced therapies (median 5, IQR 4-6). Among patients with clinically active disease at baseline, 5/7 (71.4%) achieved clinical remission and 2/7 (28.6%) achieved clinical response without remission. All 4 ileostomy patients with active disease responded, and 2 achieved clinical remission. Eight patients had active EIMs at baseline; 7/8 (87.5%) improved, with 4 achieving resolution. Three patients discontinued DTT due to adverse events (acne [1], fatigue [1], and upper respiratory infection [1]). Conclusion: DTT with RISA and UPA is effective and safe in medically resistant CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.